COMPANY
El-Peptido (Shanghai) Biopharmaceutical Co., Ltd
El-Peptido (Shanghai) Biopharmaceutical Co., Ltd: bulk ingredient labeler for BPC-157, Bremelanotide, CJC-1295, DSIP, GHK-Cu, Ipamorelin, KPV, Melanotan II, MOTS-c, Oxytocin, Semaglutide, Sermorelin, TB-500, Tesamorelin, Tirzepatide, as stated by public registers.
BULK INGREDIENT LABELER
Lists the bulk active ingredient with FDA (NDC directory).
| BPC-157 | BPC-157 Acetate, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
|---|---|
| Bremelanotide | Bremelanotide Acetate, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
| CJC-1295 | CJC-1295 Acetate, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
| DSIP | DSIP Acetate, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
| GHK-Cu | Copper Peptide(GHK-Cu), BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
| Ipamorelin | IPAMORELIN Acetate, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
| KPV | KPV, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
| Melanotan II | MELANOTAN II, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
| MOTS-c | MITOCHONDRIA-DERIVED PEPTIDE MOTS-C, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
| Oxytocin | Oxytocin, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
| Semaglutide | SEMAGLUTIDE, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
| Sermorelin | Sermorelin Acetate, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
| TB-500 | TB-500, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
| Tesamorelin | Tesamorelin Acetate, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
| Tirzepatide | TIRZEPATIDE, BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING Regulator openFDA |
What a register states, not an endorsement or an accusation by this site. All companies.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.